F
Frank C. Marini
Researcher at Wake Forest Institute for Regenerative Medicine
Publications - 129
Citations - 32441
Frank C. Marini is an academic researcher from Wake Forest Institute for Regenerative Medicine. The author has contributed to research in topics: Mesenchymal stem cell & Stem cell. The author has an hindex of 52, co-authored 128 publications receiving 29069 citations. Previous affiliations of Frank C. Marini include University of Texas System & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Massimo Dominici,K. Le Blanc,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Diane S. Krause,Robert J. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz +9 more
TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
Journal ArticleDOI
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement
Edwin M. Horwitz,K. Le Blanc,Massimo Dominici,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Robert J. Deans,Diane S. Krause,Armand Keating +8 more
TL;DR: The mesenchymal stromal cells (MSC) as mentioned in this paper have been proposed as a more scientifically correct nomenclature for the fibroblast-like cells, regardless of the tissue from which they are isolated.
POSITION PAPER Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement
Edwin M. Horwitz,K Le Blanc,Massimo Dominici,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Robert J. Deans,Diane S. Krause,Armand Keating +8 more
TL;DR: It is suggested that the fibroblast-like plastic-adherent cells, regardless of the tissue from which they are isolated, be termed multipotent mesenchymal stromal cells, while the term mesenchyal stem cells is used only for cells that meet specified stem cell criteria.
Journal ArticleDOI
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Akira Nakamizo,Frank C. Marini,Toshiyuki Amano,Asadullah Khan,Matus Studeny,Joy Gumin,Julianne Chen,Stephen J. Hentschel,Giacomo G. Vecil,Jennifer L. Dembinski,Michael Andreeff,Frederick F. Lang +11 more
TL;DR: It is concluded that hMSCs can integrate into human gliomas after intravascular or local delivery, that this engraftment may be mediated by growth factors, and that this tropism of hMSC for human gl iomas can be exploited to therapeutic advantage.
Journal ArticleDOI
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva,Rooha Contractor,Twee Tsao,Ismael Samudio,Peter P. Ruvolo,Peter P. Ruvolo,Shinichi Kitada,Xingming Deng,Dayong Zhai,Yue Xi Shi,Thomas Sneed,Monique Verhaegen,Maria S. Soengas,Vivian Ruvolo,Teresa McQueen,Wendy D. Schober,Julie C. Watt,Tilahun Jiffar,Xiaoyang Ling,Frank C. Marini,David Harris,Martin Dietrich,Zeev Estrov,James A. McCubrey,W. Stratford May,John C. Reed,Michael Andreeff +26 more
TL;DR: ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells, suggesting that ABT- 737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered.